Condition: Glioblastoma · Sponsor: Johann Wolfgang Goethe University Hospital
The main objective of this clinical study is to evaluate the safety and tolerability of NK-92/5.28.z and to determine the maximum tolerated dose or maximum feasible dose (MFD). Recommended phase 2 doses both for intraoperative injections only (RP2Diio) and repetitive injections (RP2Dri) will be determined. Frequent side effects and target organs of toxicity and their severity, duration and reversibility will be determined. Furthermore, pharmacokinetics and pharmacodynamics will be examined. In addition, potential signs of anti-tumor activity of NK-92/5.28.z cells will be analyzed. In the separate "CAR2BRAIN-Check" and "CAR2BRAIN-CheckR" cohorts, combination therapy of NK-92/5.28.z with the anti-PD-1 antibody Ezabenlimab (BI 754091) will be tested.
This description comes directly from the study's public registry record.
Michael C Burger, PD Dr. med. · 0049696301 · michael.burger@unimedizin-ffm.de
Always discuss trial participation with your own doctor first.
| Neurochirurgische Klinik, Universitätsklinikum Heidelberg | Heidelberg, Baden-Wurttemberg, Germany | Recruiting |
| Neurochirurgische Klinik, Universitätsmedizin Mannheim | Mannheim, Baden-Wurttemberg, Germany | Recruiting |
| Neurochirurgische Klinik, Universitätsmedizin Mainz | Mainz, Rhineland-Palatinate, Germany | Recruiting |
| Johann W. Goethe University Hospital, Department of Neurosurgery | Frankfurt, Germany | Recruiting |
| Johann W. Goethe University Hospital, Senckenberg Institute of Neurooncology | Frankfurt, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03383978